Hybridoma technology utilizes a wide variety of experimental procedures to yield antigen-specific monoclonal antibody (mAb)-producing immortal hybridoma clones.
Conventional hybridoma technology utilizes in vivo immunizations, cell:cell fusion, specialized cell culture conditions, and various screening techniques to yield antigen-specific monoclonal antibody (mAb)-producing immortal hybridoma clones. The concept is essentially unchanged from Kohler and Milstein’s original approach reported in 1975. Animals (typically rodents) are immunized with the target antigen, splenocytes are fused with myeloma partners and grown in HAT media to select for hybridomas, and the hybridoma supernatants are screened for target reactivity. Single cell cloning is performed to yield monoclonal antibody-producing hybridomas.